M15-531 : A Randomized Phase 2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy,Treatment | Blood / Myeloma / LymphomaMyelodysplasia

Trial Overview Read MoreRead more

This phase II trial is evaluating Azacitidine alone and in combination with Venetoclax in patients with previously untreated Myelodysplastic Syndromes (MDS).
 

This trial is treating patients with Myelodysplastic Syndromes (MDS).

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomized Phase 2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Commercial Sponsor

AbbVie

Summary

This is a randomized, Phase 2, dose-ranging study to evaluate the safety, pharmacokinetics (PK), and efficacy of venetoclax administered in combination with azacitidine in participants with treatment-naïve higher-risk (HR) MDS as compared to azacitidine monotherapy.

Recruiting Hospitals Read MoreRead more

Olivia Newton-John Cancer Wellness & Research Centre
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next